Journal Menu

Special Issues

Table of Content

Advances in Cancer Immunotherapy

Submission Deadline: 31 March 2025 (closed) View: 1542 Submit to Journal

Guest Editors

Zongsheng Guo, Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, UNITED STATES. E-mail: Zongsheng.Guo@RoswellPark.org

Wenxue Ma, Department of Medicine, Sanford Stem Cell Institute and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA. wma@health.ucsd.edu

Summary

Cancer immunotherapy plays an important role in the treatment of cancer, leveraging the body's own immune system to identify and eradicate malignant cells. This revolutionary approach has shown remarkable success in various cancer types, offering new hope to patients worldwide.

This Special Issue focuses on the latest advancements in cancer immunotherapy, a rapidly evolving field that harnesses the body’s immune system to combat cancer. We invite researchers to submit original research articles, comprehensive reviews, and insightful case studies that explore innovative immunotherapeutic approaches, including immune checkpoint inhibitors, CAR T-cell therapy, cancer vaccines, and novel biomarkers. Contributions that address mechanisms of resistance, combination therapies, and translational research bridging laboratory findings to clinical applications are particularly encouraged. Our goal is to compile a diverse collection of pioneering studies that will drive forward the understanding and effectiveness of immunotherapy in oncology. Join us in advancing the fight against cancer through the power of the immune system.

Keywords

1. Cancer immunotherapy
2. Immune checkpoint inhibitors
3. CAR T-cell therapy
4. Cancer vaccines
5. Novel biomarkers

Published Papers

Show export options

Open Access

REVIEW

Universal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges
Jianan Lei, Zhuona Ni, Ruidi Zhang
Oncology Research, Vol.33, No.11, pp. 3347-3373, 2025, DOI:10.32604/or.2025.067445
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract This review aims to explore the development, challenges, and future directions of UCAR cell therapy as a scalable alternative to autologous CAR-T for cancer treatment. Consequently, limitations of autologous CAR-T, including long production, variable quality, and cost, drive off-the-shelf UCAR development to standardize manufacturing and improve access. Current UCAR-T cell strategies focus on mitigating the risks of graft-vs.-host disease and host-vs.-graft rejection through advanced gene editing technologies, including clustered regularly interspaced short palindromic repeat-associated system Cas9-mediated knockout of the T cell receptor, human leukocyte antigen, and cluster of differentiation 52 (CD52). Beyond conventional T cells, cell… More >

View
1616

Download
394
Open Access

REVIEW

Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Current Evidence and Future Directions
Takeshi Toyozumi, Hideaki Shimada, Hisahiro Matsubara
Oncology Research, Vol.33, No.11, pp. 3185-3206, 2025, DOI:10.32604/or.2025.065818
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Cancer immunotherapy has long been established as an important treatment option for cancers. In particular, Immune Checkpoint Inhibitor (ICI) has been reported to be effective against various gastrointestinal cancers (esophageal cancer, gastric cancer, colorectal cancer); however, the treatment phase in which ICI should be used and how it should be incorporated into the treatment strategy vary depending on the cancer type being treated. Multiple clinical trials and basic research on ICIs are currently underway, and new insights from these results will continue to change the clinical treatment strategy of gastrointestinal cancers. While it is desirable… More >

View
948

Download
229
Open Access

REVIEW

Efficacy of Immune Checkpoint Inhibitors in the Treatment for Head and Neck Cancer Patients: A Systematic Review and Network Meta-Analysis
Jiao Li, Nurhayu Ab Rahman, Suharni Mohamad, Guang Yang, Caixia Zhao
Oncology Research, Vol.33, No.9, pp. 2263-2278, 2025, DOI:10.32604/or.2025.065911
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Objectives: Checkpoint inhibitors have significantly improved outcomes in a number of malignancies. To determine the most effective course of treatment for head and neck squamous cell carcinoma (HNSCC), this systematic review evaluated the efficacy of several therapeutic approaches based on immune checkpoint inhibitors (ICIs). Methods: A comprehensive evaluation of the literature was conducted, looking at randomized controlled trials (RCTs) that were published in Embase, PubMed, and the Cochrane Central Register of Controlled Trials since database establishment. The risk of bias of the enrolled studies was analyzed using The Review Manager (RevMan) 5.4. Using network meta-analyses… More >

View
1813

Download
1173
Open Access

REVIEW

Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma
Jiahao Xue, Jingchang Zhang, Gang Chen, Liucui Chen, Xinjun Lu
Oncology Research, Vol.33, No.9, pp. 2309-2329, 2025, DOI:10.32604/or.2025.063719
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Hepatocellular carcinoma (HCC) is a highly aggressive malignancy, largely driven by an immunosuppressive tumor microenvironment (TME) that facilitates tumor growth, immune escape, and resistance to therapy. Although immunotherapy—particularly immune checkpoint inhibitors (ICIs)—has transformed the therapeutic landscape by restoring T cell-mediated anti-tumor responses, their clinical benefit as monotherapy remains suboptimal. This limitation is primarily attributed to immunosuppressive components within the TME, including tumor-associated macrophages, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs). To address these challenges, combination strategies have been explored, such as dual checkpoint blockade targeting programmed cell death protein 1 (PD-1), programmed death-ligand More >

View
2034

Download
1274
Open Access

REVIEW

The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review
MICHELE MAFFEZZOLI, GIULIA CLAIRE GIUDICE, GIACOMO IOVANE, MARTINA MANINI, ELENA RAPACCHI, GIUSEPPE CARUSO, NICOLA SIMONI, STEFANIA FERRETTI, STEFANO PULIATTI, DAVIDE CAMPOBASSO, SEBASTIANO BUTI
Oncology Research, Vol.33, No.4, pp. 741-757, 2025, DOI:10.32604/or.2024.057278
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Background: immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic urothelial carcinoma (mUC), significantly improving survival outcomes. However, a subset of patients do not respond to ICIs, prompting research into potential predictive factors. Commonly prescribed medications such as corticosteroids, proton-pump inhibitors (PPIs), antibiotics (Abs), antihypertensives, and analgesics may influence ICI effectiveness. Methods: we conducted a literature search on PubMed to investigate the impact of concomitant medications on the outcomes of patients with mUC, treated with ICIs. We selected the most relevant studies and performed a narrative review. Results: corticosteroids, PPIs and Abs have been associated More >

View
2273

Download
1466
Open Access

ARTICLE

Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development
WEITAO ZHENG, DONG JIANG, SONGEN CHEN, MEILING WU, BAOQI YAN, JIAHUI ZHAI, YUNQIANG SHI, BIN XIE, XINGWANG XIE, KANGHONG HU, WENXUE MA
Oncology Research, Vol.32, No.12, pp. 1837-1850, 2024, DOI:10.32604/or.2024.056565
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Objectives: The Kirsten rat sarcoma virus (KRAS) G12D oncogenic mutation poses a significant challenge in treating solid tumors due to the lack of specific and effective therapeutic interventions. This study aims to explore innovative approaches in T cell receptor (TCR) engineering and characterization to target the KRAS G12D_7-16 mutation, providing potential strategies for overcoming this therapeutic challenge. Methods: In this innovative study, we engineered and characterized two T cell receptors (TCRs), KDA11-01 and KDA11-02 with high affinity for the KRAS G12D_7-16 mutation. These TCRs were isolated from tumor-infiltrating lymphocytes (TILs) derived from tumor tissues of patients More >

View
1933

Download
863
Open Access

REVIEW

mRNA vaccines: a new era in vaccine development
SHUBHRA CHANDRA, JENNIFER C. WILSON, DAVID GOOD, MING Q. WEI
Oncology Research, Vol.32, No.10, pp. 1543-1564, 2024, DOI:10.32604/or.2024.043987
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body’s innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized… More >
Graphic Abstract

View
4976

Download
2770

Advances in Cancer Immunotherapy

Guest Editors

Summary

Keywords

Published Papers

View

1616

Download

394

View

948

Download

229

View

1813

Download

1173

View

2034

Download

1274

View

2273

Download

1466

View

1933

Download

863

View

4976

Download

2770

Further Information

Guidelines

Follow Us

Join Us

Contact Us

WhatsApp:

Share Link